Search
MG98
go.drugbank.com/drugs/DB06544ExperimentalMG98, a second-generation antisense oligodeoxynucleotide inhibitor of human DNMT1, was investigated in the completed clinical trial NCT00003890 for treating patients with advanced solid tumors.
Pascolizumab
go.drugbank.com/drugs/DB06560InvestigationalPascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.
Categories: Amino Acids, Peptides, and ProteinsOrnipressin
go.drugbank.com/drugs/DB13464ExperimentalCategories: Pituitary and Hypothalamic Hormones and Analogues, Sex Hormones and InsulinsNelistotug
go.drugbank.com/drugs/DB19334Investigationalin clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous Cell Carcinoma of the Head and
Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)-
go.drugbank.com/drugs/DB16204InvestigationalIsoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and Safety of Oral Administration of SSR150106XB for
Osoresnontrine
go.drugbank.com/drugs/DB16274InvestigationalOsoresnontrine is under investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks
Alpibectir
go.drugbank.com/drugs/DB21561InvestigationalAlpibectir is under investigation in clinical trial NCT06748937 (A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide).
Ceperognastat
go.drugbank.com/drugs/DB21591InvestigationalCeperognastat is under investigation in clinical trial NCT05063539 (A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease).
Ranosidenib
go.drugbank.com/drugs/DB21727InvestigationalRanosidenib is under investigation in clinical trial NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia).